Podcasts about medwatch

Dr. Rodolfo Estrada, is a seasoned pulmonologists currently at UT Health San Antonio with significant experience in the management of patients with different forms of pulmonary hypertension. In this episode, Dr. Estrada will discuss the technology and clinical development behind YUTREPIA™ (treprostinil) inhalation powder and why it might be a good option for some PAH and PH-ILD patients. This Special Edition episode is sponsored by Liquidia. Please see the Important Safety Information following this podcast. The Prescribing Information and Instructions for Use for YUTREPIA (treprostinil) inhalation powder are available at YUTREPIA.com.  YUTREPIA is approved for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve the ability to exercise. Please see the Important Safety Information in the show notes. The Prescribing Information and Instructions for Use for YUTREPIA are available at YUTREPIA.com. Learn more about the INSPIRE study. Learn more about pulmonary hypertension trials at www.phaware.global/clinicaltrials. Engage for a cure: www.phaware.global/donate #phaware Share your story: info@phaware.com Like, Subscribe and Follow us: www.phawarepodcast.com. #phawareMD #PHILD @Liquidia_Corp @REstradaMD @UTHealthSA IMPORTANT SAFETY INFORMATION Before you take YUTREPIA, tell your healthcare provider about all of your medical conditions, including if you: Have low blood pressure Have or have had bleeding problems Have asthma or chronic obstructive pulmonary disease (COPD) Are pregnant or plan to become pregnant. It is not known if this product will harm your unborn baby Are breastfeeding or plan to breastfeed. It is not known if this product passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. YUTREPIA and other medicines may affect each other. Especially tell your healthcare provider if you take: Medicines used to treat high blood pressure or heart disease Medicines that decrease blood clotting (anticoagulants) Water pills (diuretics) Gemfibrozil (Lopid®) or rifampin (Rimactane®, Rifadin®, Rifamate®, Rifater®) What are the possible side effects of YUTREPIA? This product can cause serious side effects, including: Low blood pressure (symptomatic hypotension). If you have low blood pressure, this product may lower your blood pressure more. Bleeding problems. This product may increase the risk of bleeding, especially in people who take blood thinners (anticoagulants). The most common side effects of YUTREPIA are cough, headache, throat irritation and pain, nausea, reddening of the face and neck (flushing), fainting or loss of consciousness, dizziness, diarrhea, and shortness of breath. Like other inhaled prostaglandins, you may have trouble breathing after taking YUTREPIA because it may cause the muscles around your airway to tighten (bronchospasm). These are not all the possible side effects. Call your doctor for medical advice about side effects or if you have trouble breathing. You may report side effects to the FDA at www.fda.gov/MedWatch or call 1–800-FDA-1088. The risk information provided here is not comprehensive. To learn more about YUTREPIA, talk with your healthcare provider. Please see Full Prescribing Information for YUTREPIA and Instructions for Use. For additional information, call 1–888–393–5732.

Happy New Year, and welcome back to The Richer Geek Podcast! In this episode, Daniel Barnard, host of CapitalFit and experienced investor, shares tips on raising capital, building networks, and growing your business. With 27 years in the industry, Daniel offers practical advice for entrepreneurs on securing funding and attracting the right partners. Join us as we dive into Daniel's expertise, his work with startups like MedWatch, and his passion for creating impactful ventures.  In this episode, we're discussing... The Role of a Connector: Learn how Daniel bridges the gap between founders and investors to fuel business growth. Capital Raising Insights: Explore strategies for raising capital, from crowdfunding to angel investing, and what it takes to succeed. Reinvention Through Passion: Discover how Daniel pivoted from a 25-year career in finance to building impactful ventures in MedTech and beyond. The Power of Intentional Networking: Hear how focus, prayer, and alignment help attract the right opportunities and people at the right time.   Resources from Daniel LinkedIn | CapitalFit | CapitalFit Podcast Resources from Mike and Nichole Gateway Private Equity Group |  Nic's guide

Hvorfor inviterer Novo Nordisk lægerne på gratis frokoster, middage, rejser, hotelophold, konferencer i udlandet og efteruddannelse i Danmark? Det undersøger vi i seriens tredje afsnit, hvor vi også ser nærmere på offentlige læger, der vælger at arbejde for Novo Nordisk i fritiden. Ifølge Novo Nordisks øverste chef, Lars Fruergaard Jørgensen, er tætte relationer til lægerne en konkurrenceforel for den danske medicinalkoncern. Lyt her til episode 3 af 3 af podcastserien Gyldne dråber, der er en særudgave af Sorte tal. Kilder: Vi har bl.a. bragt oplysninger fra Novo Nordisks investorinformation, podcasten Ledelse Med Vilje fra Lederstof.dk, podcasten Topchefernes strategi fra Børsen, artikelserien "Novoland" fra Berlingske Business, podcastserien "Novoland" fra Frihedsbrevet, artikler fra Medwatch, Frihedsbrevet, Berlingske, Børsen, Jyllands-Posten samt Financial Times, Wall Street Journal og Reuters om Novo Nordisk. Derudover nævner vi Sundhedsstyrelsens præparatanmeldelse om Wegovy. Tilrettelæggelse og research: Ole Hall. Lyddesign: Jonas Johs Andersen. Dramaturgisk konsulent: Anne Pilegaard Petersen. Programansvarlige: Sofie Tholl og Michael Alsen. Har du oplysninger, du vil dele? Skriv til journalist Ole Hall på oleh@dr.dk

Hvad har Hollywood-influencere, talkshows og TV-dokumentarer med Novo Nordisk at gøre? Den danske medicinalkoncern har betalt for det hele. Det sker for at præge samtalen om overvægt, og det viser sig, at topchefen i Novo Nordisk har spillet en nøglerolle i det, som eksperter betegner som en stor PR- og lobbykampagne. Lyt her til episode 2 af 3 af podcastserien Gyldne dråber, der er en særudgave af Sorte tal. Kilder: Vi har bl.a. bragt oplysninger fra Novo Nordisks investorinformation, podcasten Ledelse Med Vilje fra Lederstof.dk, podcasten Topchefernes strategi fra Børsen, artikelserien "Novoland" fra Berlingske Business, podcastserien "Novoland" fra Frihedsbrevet, artikler fra Medwatch, Frihedsbrevet, Berlingske, Børsen, Jyllands-Posten samt Financial Times, Wall Street Journal og Reuters om Novo Nordisk. Derudover nævner vi Sundhedsstyrelsens præparatanmeldelse om Wegovy. Tilrettelæggelse og research: Ole Hall. Lyddesign: Jonas Johs Andersen. Dramaturgisk konsulent: Anne Pilegaard Petersen. Programansvarlige: Sofie Tholl og Michael Alsen. Har du oplysninger, du vil dele? Skriv til journalist Ole Hall på oleh@dr.dk

Hvordan skabte Novo Nordisk en af de største økonomiske succeser i dansk erhvervsliv nogensinde? Det undersøger DR's erhvervsjournalist Ole Hall. Han kommer på sporet af en sensationel medicinsk opfindelse og det, som eksperter kalder en omfattende og årelang PR- og lobbykampagne søsat af Novo Nordisk. Lyt her til episode 1 af 3 af podcastserien Gyldne dråber, der er en særudgave af Sorte tal. Kilder: Vi har bl.a. bragt oplysninger fra Novo Nordisks investorinformation, podcasten Ledelse Med Vilje fra Lederstof.dk, podcasten Topchefernes strategi fra Børsen, artikelserien "Novoland" fra Berlingske Business, podcastserien "Novoland" fra Frihedsbrevet, artikler fra Medwatch, Frihedsbrevet, Berlingske, Børsen, Jyllands-Posten samt Financial Times, Wall Street Journal og Reuters om Novo Nordisk. Derudover nævner vi Sundhedsstyrelsens præparatanmeldelse om Wegovy. Tilrettelæggelse og research: Ole Hall. Lyddesign: Jonas Johs Andersen. Dramaturgisk konsulent: Anne Pilegaard Petersen. Programansvarlige: Sofie Tholl og Michael Alsen. Har du oplysninger, du vil dele? Skriv til journalist Ole Hall på oleh@dr.dk

Themen; Wie viele Journalisten sterben in Gaza?; EU-Berichterstattung - Was passiert da?; Euractiv - Berichten über die EU; Medwatch: Wichtig aber nicht profitabel; Wo ist das?" Geospy AI und die Folgen; Medienschelte: FC Bayern: Die Trainersuche der Medien; Moderation: Anja Backhaus Von WDR 5.

Stellt euch eine Welt vor, in der medizinische Informationen einen Faktencheck unterzogen werden und es unabhängige Quelle gibt, die dir Hintergrundinfos geben, wenn du wissen willst, ob dieses Präparat von dem alle reden wirklich so gut ist wie alle oder eben social media sagen. An diese Vision arbeitet Nicola Kuhrt. Sie ist Wissenschaftsjournalistin, Autorin und Gründerin von mehreren Projekten, unteranderem der Plattform Medwatch. Medwatch ist ein journalistisches Netzwerk, was immer wieder medizinische Fake News entlarvt und dubiose Heilsversprechen in den Blick nimmt. Wir sprechen in dieser Folge darüber, wie gefährlich solche Fake News sein können, wie wir sie schneller entdecken können und wir wir langfristig mit medizinischen Falschinformationen in der Gesellschaft umgehen müssen. Alle weiterführenden Informationen sowie ein Transkript der Folge findet ihr unter www.heileweltpodcast.com Bei Fragen, Anregungen oder Kritik schreibt uns gerne an heile.welt@posteo.de oder auf instagram @heilewelt.podcast

Nahrungsergänzungsmittel wie Omega 3-Kapseln, Vitamin D-haltige Produkte oder Mineralstoffe werden Jahr für Jahr populärer. Umfragen zufolge nehmen 75 Prozent der Deutschen regelmäßig ein oder mehrere solcher Produkte zu sich. Dahinter steht ein Markt, der allein für Deutschland mittlerweile auf drei Milliarden Euro pro Jahr geschätzt wird. Aber wie sinnvoll sind die Mittel eigentlich? „Bei Nahrungsergänzungsmitteln ist es tatsächlich so, dass das meiste überflüssig ist“, sagt Sigrid März im Podcast „Die Stunde Null“. Die promovierte Zellbiologin leitet Medwatch, ein Rechercheprojekt, das sich auf die Analyse der Produkte und der Werbung dafür spezialisiert hat. „Wenn ein gesunder Mensch sich abwechslungsreich ernährt, nimmt er alle nötigen Nährstoffe auf.“ Im besten Fall seien viele der Mittel schlicht „teurer Urin“, da der Körper die Stoffe einfach wieder ausscheide. Im schlimmsten Fall könne es jedoch auch zu Schäden kommen. „Gefährlich wird es dann, wenn der Körper diese Stoffe sammelt“, sagt März. „Das gilt zum Beispiel für die fettlöslichen Vitamine, die nicht ausgespült werden, wenn man sie in zu hoher Dosierung aufnimmt.“ Für problematisch hält März daher aggressive Werbung, die ein Heilsversprechen mit sich bringt. „Ich denke schon, dass es da eine Regulierungslücke gibt, in Deutschland und EU-weit“, sagt sie. „Es gibt schon lange Bestrebungen, diese Lücke zu schließen, aber bisher ist da nichts passiert.“ // Weitere Themen: Was bedeutet der blockierte Suezkanal für die Wirtschaft? +++Eine Produktion der Audio Alliance.Hosts: Nils Kreimeier und Martin Kaelble.Redaktion: Lucile Gagnière.Produktion: Andolin Sonnen. +++60 Tage lang kostenlos Capital+ lesen - Zugriff auf alle digitalen Artikel, Inhalte aus dem Heft und das ePaper. Unter Capital.de/plus-gratis +++Weitere Infos zu unseren Werbepartnern finden Sie hier: https://linktr.ee/diestundenull +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://datenschutz.ad-alliance.de/podcast.html +++Unsere allgemeinen Datenschutzrichtlinien finden Sie unter https://art19.com/privacy. Die Datenschutzrichtlinien für Kalifornien sind unter https://art19.com/privacy#do-not-sell-my-info abrufbar.

Ihm wurden zwei ungeteilte Nobelpreise verliehen. Das hat außer Linus Pauling niemand geschafft. Vieles, was er in seinem Leben erarbeitet, ist heute Chemie-Standard. Er ist Forscher und Friedensaktivist. Im letzten Drittel seines Lebens driftet er jedoch in die Pseudowissenschaft ab. Glaubt man einem Nobelpreisträger, der Quatsch erzählt? Klar! Wetten, du glaubst auch, dass Vitamin C bei Erkältung hilft? ;-) Mit dieser Folge seid ihr top auf die Erkältungssaison vorbereitet. Eine von Paulings Reden in Deutschland zur Rüstungspolitik: https://bitly.ws/33hEr Helfen Vitamin C-Infusionen gegen Krebs? (medizin transparent): https://bitly.ws/33hEx Wer kontrolliert verbotene Werbeversprechen? (MedWatch): https://bitly.ws/33hJ2 Willkommen zu unserem True Science-Podcast! Wir reden über die absurden, irren, romantischen und verworrenen Geschichten hinter Entdeckungen und Erfindungen. Denn in der Wissenschaft gibt es jede Menge Gossip! Wir erzählen zum Beispiel, wie die Erfinderin des heutigen Schwangerschaftstests mit Hilfe einer Büroklammerbox den Durchbruch schaffte, oder wie eine Hollywood-Schauspielerin den Grundstein für unser heutiges WLAN legte. Immer samstags - am Science-Samstag. Wir, das sind Marie Eickhoff und Luisa Pfeiffenschneider. Wir haben Wissenschaftsjournalismus studiert und die Zeit im Labor schon immer lieber zum Quatschen genutzt. Schreibt uns: podcast@behindscience.de I Instagram: @behindscience.podcast Hinweis: Die Werbung in dieser Folge erfolgt automatisiert. Wir haben keinen Einfluss auf die Auswahl. Vermarktung: Julep Media GmbH | Grafikdesign: Mara Strieder | Sprecherin: Madeleine Sabel | Fotos: Fatima Talalini

In the Locked On Fantasy Basketball podcast, Josh Lloyd discusses the NBA injury report for all 30 teams, including updates on De'Aaron Fox's ankle injury and Cam Johnson's calf. The podcast is sponsored by Basketball Monster.Support Us By Supporting Our SponsorsPrizePicksGo to PrizePicks.com/lockedonnba and use code lockedonnba for a first deposit match up to $100!GametimeDownload the Gametime app, create an account, and use code LOCKEDONNBA for $20 off your first purchase.FanDuelScore early this NFL season with FanDuel, America's Number One Sportsbook! Right now, NEW customers get ONE HUNDRED AND FIFTY DOLLARS in BONUS BETS with any winning FIVE DOLLAR MONEYLINE BET! That's A HUNDRED AND FIFTY BUCKS – if your team wins!  Visit FanDuel.com/LOCKEDON to get started.FANDUEL DISCLAIMER: 21+ in select states. First online real money wager only. Bonus issued as nonwithdrawable free bets that expires in 14 days. Restrictions apply. See terms at sportsbook.fanduel.com. Gambling Problem? Call 1-800-GAMBLER or visit FanDuel.com/RG (CO, IA, MD, MI, NJ, PA, IL, VA, WV), 1-800-NEXT-STEP or text NEXTSTEP to 53342 (AZ), 1-888-789-7777 or visit ccpg.org/chat (CT), 1-800-9-WITH-IT (IN), 1-800-522-4700 (WY, KS) or visit ksgamblinghelp.com (KS), 1-877-770-STOP (LA), 1-877-8-HOPENY or text HOPENY (467369) (NY), TN REDLINE 1-800-889-9789 (TN)TikTokInstagram Learn more about your ad choices. Visit podcastchoices.com/adchoices

In the Locked On Fantasy Basketball podcast, Josh Lloyd discusses the NBA injury report for all 30 teams, including updates on De'Aaron Fox's ankle injury and Cam Johnson's calf. The podcast is sponsored by Basketball Monster. Support Us By Supporting Our Sponsors PrizePicks Go to PrizePicks.com/lockedonnba and use code lockedonnba for a first deposit match up to $100! Gametime Download the Gametime app, create an account, and use code LOCKEDONNBA for $20 off your first purchase. FanDuel Score early this NFL season with FanDuel, America's Number One Sportsbook! Right now, NEW customers get ONE HUNDRED AND FIFTY DOLLARS in BONUS BETS with any winning FIVE DOLLAR MONEYLINE BET! That's A HUNDRED AND FIFTY BUCKS – if your team wins!  Visit FanDuel.com/LOCKEDON to get started. FANDUEL DISCLAIMER: 21+ in select states. First online real money wager only. Bonus issued as nonwithdrawable free bets that expires in 14 days. Restrictions apply. See terms at sportsbook.fanduel.com. Gambling Problem? Call 1-800-GAMBLER or visit FanDuel.com/RG (CO, IA, MD, MI, NJ, PA, IL, VA, WV), 1-800-NEXT-STEP or text NEXTSTEP to 53342 (AZ), 1-888-789-7777 or visit ccpg.org/chat (CT), 1-800-9-WITH-IT (IN), 1-800-522-4700 (WY, KS) or visit ksgamblinghelp.com (KS), 1-877-770-STOP (LA), 1-877-8-HOPENY or text HOPENY (467369) (NY), TN REDLINE 1-800-889-9789 (TN) TikTok Instagram Learn more about your ad choices. Visit podcastchoices.com/adchoices

He's here, he's there; Dr. Hillman brings drug safety everywhere! So given the rules and regulations he needs to follow, the title “vigilante” could be nothing but ironic.We chart David's progress through choosing pharmacology as a subject to study, and settling on pharmacovigilance as a career to pursue. Listen: The Bollywood beats come courtesy of Cambridge-based artist Anish Kumar whose music you can also find on Bandcamp: anishkumarmusic.bandcamp.com, YouTube, Instagram and Twitter.Watch:Subscribe to our YouTube channel now for all future recordings. Episode transcript[Background intro music playing is "Nazia" by Anish Kumar]Parmvir: Hello everyone. And welcome to another episode of the 2Scientists podcast, where inspiring scientists share their work with you, wherever you like to listen. Today we come to you from a rather unique spot, rather than a cafe or bar we are camped out in Kensington Gardens in London, because it's a glorious day and our podcasting equipment allows us to do that. But enough about me and us, we are here today, of course I am your host Parmvir Bahia here and we're here with David Basanta, but we also have with us another David who is very special to me, he is an old friend of mine from my PhD program, and we shared much time and much swearing over experiments together at University college London. How are you David Hillman? David: I'm doing well. Thank you. It's, as you say, it's a, it's a lovely day and, it's nice to be back with old friends. Parmvir: Yes, yes. Of course everything rotates background to COVID and whereas we would normally see each other once a year. It's been three, four, possibly? David: Three, I think that's yeah.Parmvir: Miserable. David: Yeah. Sad times we shall have to make up for it. Parmvir: We will, we will. There's a bottle of Cava with our name on it. Once we've done with this. David: And onion rings. Parmvir: And onion rings. Yes. Fancy Marks and Spencer's one's though. So let's start at the beginning. I'm not talking about like, where were you born kind of thing. Although you can mention Kidderminster if you'd like. So as I understand it, we had a relatively similar track as undergraduates. So you did a bachelor's in pharmacology, correct? David: Yeah, that's right. Parmvir: So tell us why, why pharmacology? David: So this is gonna age me, age us.So I, for my A levels, so for my senior school exams, I, studied chemistry, biology, and maths, and I wanted to study something at university that combined chemistry and biology. And so this is the bit that will age us. So back in the day, if you remember, you would go to the, career advice department who were trying to help people to steer people towards what options they might want to pick at university.And they had this huge telephone directory effectively, which, mapped together people's different, combinations of A level courses and then gave you a list of options that you could, study at university. So I was sat in this little tiny room with this career advisor person, and they were basically running through this list of different courses.And when they came to pharmacology, they'd already mentioned pharmacy, which, you know, most people know what it is, but then they said pharmacology and I stopped them and said, well, what's, what's the difference? And they actually gave a pretty good summary. They said, it's more the biology of medicine. It's more the, the research and development of new medicines. They said it's potentially a controversial topic because it's the pharmaceutical industry is itself sometimes controversial and there's other aspects to the industry, which are, challenging sometimes. But yeah, that's how it started. So I picked a few different pharmacology courses, one of which was King's College London. I was always very practical, so I liked the idea of doing a year in industry at some point. So I chose a sandwich course like you and yeah, so that took me to KCL all that time ago. Parmvir: Mm. So I didn't realize how similar our tracks had been, because I also did biology, chemistry and maths, and I wanted to do something with the chemistry and the biology.And I got put in that direction by David: did you pick it out of the phone book as well? Parmvir: I did. What was it called? There was a name for it. David: It was pretty like a UCAS publication. Parmvir: Yes. It was just, it was enormous. David: Yeah. Parmvir: But yeah, in any case, I also, I did a sandwich year and I got to go and hang out in Germany for a year, which was fun.But yeah. So obviously after that you came to do a PhD at UCL where we were, well, I was a year ahead of you, I think. David: Yeah. You were. Parmvir: Why? Why did you do a PhD? David: So well for the reasons that I guess a lot of people do them, which is that I wasn't sure what to do next [both laugh] and a PhD seemed like a good way to string it out for another few years before I figured that out.But the reason I landed on UCL was that when I did go and do my year in industry, which like you was for a large pharma company, I worked in a lab looking at some non-clinical safety models. And we were using electrophysiology techniques at the time that was sharp electrode electrophysiology.Parmvir: You're gonna have to explain what electrophysiology means. David: Oh, don't make me do that. It's been 20 years [Parmvir laughs]. Oh, it's basically where you take either isolated cells or tissues and you put tiny, tiny electrodes into them and measure the changing currents across cell membranes. And as you put different drugs on, you can look at different effects of those drugs how they affect the electrical signals that you can measure.And really it's ions moving back and forward across membranes by little things called ion channels. So yeah, so I'd done sharp electrode electrophysiology there. I went back to university to finish my last year, and then the question came up about what to pick for a PhD. And I thought, well, although I hadn't enjoyed electrophysiology, it's something that I had started to, I guess, gain an interest in. Plus I had some skills that in that area. So, yeah, so I found a course, rather a PhD studentship at UCL, which seemed to fit the bill. It was looking at using a slightly different electrophysiology technique, so patch, clamping in a different area, but I thought it was something that I could use what I'd learnt in my year in industry Parmvir: I gave you some of these questions beforehand. David: Yes, because I'm incapable of spontaneous reaction to questions [Parmvir laughs]. Parmvir: Actually, I loved it so much that I have to read out your description of what your memory is like. David: I was quite proud of that. I coined that yesterday. I used to think of my memory as a lobster pot. Parmvir: All right. So you said I've just come up with a good analogy for my recall memory. It's like a reference library. You have to put in a request and then go away for a bit. When you come back, I'll have retrieved something from the vaults. Hopefully. David: Yeah, exactly. Parmvir: But aside from that I wanted to say this might be something of a loaded question, but what did you think of your PhD experience?David: You know, I really, I look back on those years with fond memory. Now it's partly because looking back, you edit out all of the stress and anxiety associated with doing a research project like that. I remember at the time when I first started UCL ran some induction courses where they pulled together PhD students and other postgraduate students from all sorts of backgrounds and John Foreman who you'll remember who was the Dean of students at the time, he gave a little introduction to UCL, but also gave some interesting advice let's say and pointers.And one of the things he pointed out in that session was the high degree of mental illness that is encountered by students in general taking these types of courses because they are stressful. And you often feel like you are kind of on your own. Driving your own research project forward. Sometimes through difficult times. So I do remember that in particular, but you know, what I remember mostly is just how impressed I was with all of the people that surrounded me because our department was not particularly flashy in its kind of presentation, but there were some seriously impressive people there.So I always like to think of our lab in the sense of, you know, it was run by effectively by Dennis and, and Guy when we got there. But before then it had been run by Don and before then it had been run by Bernard Katz who was a Nobel laureate. So it felt like we were the either grandchildren or great grandchildren of a Nobel Laureate and the whole department was a bit like that. It had a lot of very understated people who were world experts in their, in their field. And I always felt like the dumbest person in the department. But that didn't bother me too much because you know, being surrounded by all this greatness and even just, you know, the little glimpses of things you would see at the kind of coffee breaks and in the corridors, some of those memories still live with me, you know. Bearing in mind, this was back in what, between 2001 and 2005.So very, very early days of smartphones, things like trios and things like that, which seem antiquated now. But I remember coming across two old professors, so probably in their seventies or eighties comparing their smartphones and that like little microcosm, are the things that I loved about the department.Parmvir: Actually, I mean, I think you're, you're definitely selling yourself short. Like nobody would say that you weren't smart enough to be there. And I think one of the things that kind of ties into the, the mental health aspect is that we all felt that way. David: Yeah. Parmvir: Except we didn't express it to anyone else. It's, it's utterly ridiculous. How can we all be the least smart person in the room that's just not possible. David: Yeah. Parmvir: And after that, we all got our PhDs anyway, so, you know yeah. David: I certainly have no regrets about it. And I look back on those times with, with very fond memories, for sure. Parmvir: Yeah. Just talk briefly about what you did for your project and what the difficulties were.David: So the lab that I joined, so which, which you were a part of as well, their specialty was calcium activated potassium channels. And over time, the lab had looked at these ion channels in various different settings. The project that I was given was looking at these channels in vascular endothelial cells, which was a cell type that no one in the lab had ever studied before.Parmvir: Mm. David: So one of the biggest challenges that we were hit with straight away was that no one in the lab could really help that much with firsthand experience of how to obtain these cells, how to isolate them, how to culture them, how to grow them and really how to manage those cell types. So you might well remember that, the first, probably nine months of my PhD was just spent trying to culture these cells. Parmvir: Mm-hmm David: and it started with you know, available tissue from rats and other small mammals.But then eventually we were not having success with culturing cells from those models. So I switched onto pigs and, you know, I'd done a bit of reading that, you know, these vessels, because they were much larger the blood vessels, it was easier effectively to culture cells from, so I looked in the phone book and I found the address of an abattoir out in the middle of Essex.And there began my weekly trip for getting on for two and a half years to the deepest, darkest corners of Essex to go and retrieve pig, coronary artery cells once a week. Parmvir: Yeah. And essentially you suffered because these things were so flat. [David laughs] And when you're trying to, so you, for anyone who's listening, you have to picture trying to get a very, very fine tube onto something that is incredibly flat, and essentially you need this thing to form a vacuum seal and that just wasn't gonna happen. David: No, so, you know, vascular endothelial cells, they're the cells that line blood vessels, which is why they're, they're very flat. They're like tiles almost on the inside of veins and arteries.And you know, with other cells in the lab that were being looked at like the ones that you were looking at, like DRGs and like neurons and things like that, you know, you were basically putting the, the electrode down onto like a ball. Parmvir: Yeah. David: So the gap between the bottom of the dish and the top of the cell was who knows, 10, 20 microns, something like that. The cells that we were looking at, they flattened themselves out so much, they were about one micron, I think we estimated and therefore the tiniest vibration in the room would destroy the cell. And yeah, so the first stage was trying to culture, the damn things, and that was extremely challenging. It took a long time, but nine months of the way through managed it, and then began the whole pain of trying to get electrical recordings from them, which turned out to be as difficult. Parmvir: Yeah. So one of the things, I don't know if we ever talked about this, but what did you aspire to do after you'd done your PhD originally?Like, did you have any kind of idea? David: I mean, I think I was always headed into the pharmaceutical industry, which is where I landed up. In my undergrad degree in, I think my either first or second year, I did a very nice course, which was a kind of practical introduction to the pharmaceutical industry and from very top level, how drugs are developed and how pharma companies are organized internally and how the research progresses. And that, I'd always found that interesting. I mean, I find the entire pharmaceutical industry absolutely fascinating. And still do to this day. It's such an amazingly complex industry. And so, yeah, so I think I'd always been heading in that direction. Sure enough, the PhD certainly made me decide I was done with bench science [Parmvir laughs]. So, you know, by the time you've spent three plus years plodding along with these experiments that have a success rate of one in 50 sometimes. Parmvir: Yeah. David: You know, days and weeks without getting any data, and towards the end, still being in the lab at three o'clock in the morning, trying to get something to work and breaking more and more glassware as time goes on [Parmvir laughs]Yeah, I decided I was done with bench science, although I loved being in the labs, I loved playing in the labs. But I was never that into the kind of reading of the scientific papers and that sort of thing. Once it came down to maths and things like that, I wasn't so engaged. I needed to see practical things. Parmvir: Yeah. I feel like at some point we realized we were both some kind of engineer at heart rather than David: Yeah. Maybe Parmvir: scientist, David: maybe. Parmvir: It's more like, how does this work rather than trying to answer a bigger scientific question. David: Yeah. Parmvir: But obviously you were, you were a little bit scarred by your experience there, and you ended up going off in, I guess, a very different track from what the standard academic education leads you towards. So I think at this point this might be a good place to put your disclaimer in. David: Yes. So I work in the pharmaceutical industry and over time I've worked for, and with a variety of different companies.Any of the content that I describe today are my opinions and my opinions alone, and often they're really based off things which are in the public domain. In fact it's all based off things that were in the public domain and also some of the education that I've received, because actually, even after I finished my PhD, I then years later went on to study a, another academic course specifically in pharmacovigilance and pharmacoepidemiology.Parmvir: Oh, where did you do that? David: London school of Hygiene and Tropical Medicine. Parmvir: Oh. David: And it's interesting because it's a short course and I felt was a very valuable course. It's a course where regulatory authorities also send their people to learn too. Parmvir: So there's a lot of questions I can ask next.But one of the things that your job description throws up is this word "pharmacovigilance". What does that mean? David: Okay. So somewhere because I'm not gonna do it justice from memory, I'm going to read out the WHO definition of pharmacovigilance. It doesn't roll off the tongue, unfortunately, which is why it's never quite there in my head.So per the WHO: pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects, or any other medicine, or vaccine-related problem. So essentially it is the process and the science relating to drug side effects. Now as you'll remember from pharmacology days, very early on, you're taught that all pharmacologically active substances, if it applies to the human body have side effects. The same side effects are not encountered by every person.And you know, some of the side effects might have obvious clinical manifestations. Some might not, you might get side effects, never know you've had them. And of course they vary massively in severity. So when you are looking at a medicine, particularly one that you're introducing to kind of general use in humans, you have a trade-off to make because you have an expected therapeutic benefit, but you also have to be mindful of potential side effects, particularly serious side effects and how much tolerance you have for those versus the good that the drug is supposed to do.And achieving that balance is one of the big challenges that's faced in drug development.Parmvir: So what you do really, it kind of comes at the end of the whole process of clinical trials and so on for given products, right? David: It actually starts right at the beginning of clinical development.So. Parmvir: Oh, hang on, I have to ask David's question: does that make you a Pharmacovigilante? David: [David and Parmvir laugh] I've often wondered the same thing myself. But yeah, so pharmacovigilance takes off really where toxicology leaves. So before you can put a drug into clinical development, by which I mean development in humans, drugs first have to go through preclinical development and that's where all the various toxicology studies are run.Parmvir: Can you quickly define toxicology for us? David: Sure. It is really focusing on the well, the potentially toxic side of medicines. So before you put a drug anywhere near a human, you want to be absolutely certain that it doesn't cause various catastrophic side effects in humans.So, for example, you need to be confident that it doesn't cause cancer. You need to be confident that it's not gonna cause a heart attack immediately, or cause a stroke immediately or things like that. So as per regulations in pretty much every country in the world, before you put a drug anywhere near a human in a clinical trial, it has to go through a standard set of tests.And there's various ways to achieve that. You know, sometimes those are tests using computer simulated models. Sometimes they are using individual cells or cultured cells or tissues. And sometimes as is well known in the industry they're using animal models and these are legally required tests.So every drug that goes through the process has to go through these. So that's done before it gets to clinical development. And then you start with phase one clinical trials which are studies on, usually on healthy volunteers and they're very small trials. They involve perhaps a few tens of patients. And the only purpose of those trials is to look at the safety and tolerability of the drug. So this is the first time you're putting the drug into humans. There is a bit of an exception to that. So although these are usually conducted on healthy volunteers, for some drugs, including, for example oncology drugs. Those drugs are usually along the more kind of toxic end of agents, so it's not ethical to put those into healthy volunteers. So sometimes those studies are conducted in a patient population. So once a drug moves into human studies into phase one, from that point, really for the rest of the lifetime of that drug as a human medicine pharmacovigilance is involved. So all the way through the phase one, two and three studies and then once the drug goes onto the market, pharmacovigilance continues.So the companies or the pharmaceutical or biotech companies that are developing these assets have a legal requirement to collect and analyze this data on an ongoing basis pretty much forever. Until that drug is eventually, perhaps if it's lucky enough to get to the market, until it's withdrawn from the market, perhaps many decades later.Parmvir: Very good. And I think that there are probably some very topical things that have come up recently as a result of COVID 19, which is important to consider when we're talking about these things, in that we are not just relying on these clinical trials that have gone out to ensure that these things are safe, but once they're out there that you have to continue to get feedback from people who are taking these to ensure that they continue to be safe in the long term, right?David: That's true. So, you know, ordinarily in clinical development, once you get through phase 1, 2, 3, and if you are lucky enough to have a drug, which is sufficiently efficacious, tolerable to go to market, then yes, you know, the drug's released to market and you continue to monitor for this stuff.Vaccines are in a particularly special category because they are drugs that are given to healthy people. Mm yes. And so therefore the benefit risk balance is more complicated in some ways, because , you know, it's, it's hard to consider the benefit to the individual of taking a product when they don't yet have that disease.So now there are other drugs that are in a similar category, other drugs that are given to healthy people. This is where I can ask you some questions. So what, what do you think those other drugs include? Parmvir: Oh, goodness. Um, I'm trying to think off the top of my head, what they might be. David: Yeah. It's very unfair. Parmvir: All I can think of at the moment are the other vaccines. David: Okay. So, Parmvir: but there are lots of prophylactic things. Yeah. Yeah. I can't think of anything David: Contraceptives. Parmvir: The obvious prophylactic. Yes. David: Drugs used for travel. So things like anti-malaria tablets. Parmvir: Oh yeah. David: Drugs used for things like smoking cessation Parmvir: mm-hmmDavid: stuff like that.So again, these are all drugs that are generally given to healthy people. So, you know, and this is where benefit risk balance comes into sharp focus, because if you have a drug that has been developed to treat a very hard to treat cancer, let's say, then when you consider benefit risk balance you know, if these patients are effectively going to die without a treatment, and this is the only treatment available, you might be able to accept that a drug has a one in a hundred chance of causing a fatal stroke. Particularly if that drug is given in hospital and these things can be, can be managed. If however, you are developing a cough medicine, then your tolerance for any type of dangerous side effects is basically zero, and of course, many drugs elsewhere on that scale. So yeah, benefit risk balance is a key part of what has to be looked at during drug development. And yeah, as we say, vaccines are particularly challenging. Often these days when a new drug is developed the clinical development and the studies don't stop necessarily when the drug is released for marketing. So, often as a condition of the marketing authorizations that are granted for these drugs, there have to be continuing studies to look at safety. These are called post-authorization safety studies. And so there's ongoing collection of data in a rigorous way to keep monitoring for various things. Either new things that we didn't know about the drug before, because of course when you're in clinical development, your number of patients is normally quite small Parmvir: mm-hmm David: so you're less likely to spot very rare side effects. You wouldn't usually detect a one in 50,000 probability side effect in a clinical trial cohort. Parmvir: Yeah. David: But sometimes these post authorization safety studies allow you to pick up more of that and enable you to characterize some of the side effects that you do know about more in detail.Parmvir: Yeah. So David B here asks essentially how long do these things go on after the drug's been on the market? For example, is there still pharmacovigilance for aspirin? David: Yes. Every single drug that has a marketing authorization out there it is the law in pretty much every country in the world that all safety data that becomes available to the marketing authorization holders, that's the company that owns the rights to the drug and effectively sells the drug, they're required by law to collect process, analyze and report this data. Now as drugs age, the natural reporting rate for some of these drugs drops so the probability of a physician or a pharmacist or a nurse, or even a patient reporting a side effect probably drops over time because theses are not new medicines anymore, but even so, any data that is collected has to go through that process, which is the pharmacovigilance that we were referring to earlier. In addition to that, all companies with marketing authorizations have to look at scientific and medical literature. It all has to be reviewed, so in European requirements, including the UK on a weekly basis, companies have to trawl some of the big literature databases, such as PubMed and M base, they have to trawl that information for any articles on their drugs. And any indication of side effects or other similar challenges. Parmvir: So how is this information collected and processed? Cause you've said obviously doctors, nurses, patients, they will all report certain things. Mm-hmm how do you kind of get them to a central place and cataloged and how do you decide what are actual side effects versus David: So if we think about the front end of the process, most pharma companies out there will have medical information help lines. So these are help lines that are set out there so that healthcare professionals. So that's the physicians, the, the pharmacists, the nurses and others but also consumers can contact the company for more information about the medicine and also potentially report adverse events, side effects. In parallel to that the same thing's going on with the regulators. So in the UK, for example, we have the yellow card scheme, which these days is a web portal system where anyone can go in and report side effects of medicines they're taking. In the us, you have the MedWatch scheme, which is very similar. Most companies around the world have similar things. Plus you've also got ongoing clinical trials, clinical studies, so data is coming in that way too. We've got data coming in from literature that I've mentioned. The regulators, when they receive stuff directly, they often pass that information over to the pharma company.So essentially all this information is coming towards the pharma company. It all gets directed to a pharmacovigilance department. And then we go through the process of processing that data. And so that data comes in from everywhere around the world where the drug is available for patients to take both in clinical trials and on the market.So the process basically consists of firstly translating the data, if it needs to be translated that gets captured into a safety database and there are various commercial safe databases out there. This is where companies collate all the information received on their drugs. And it goes through a process whereby data is kind of standardized it's put into standard terminology in a way that is compatible with the regulatory requirements. A narrative is constructed. So we write a story of what's happened to the patient from beginning to end. We look at various things like if the information is available to us, you know, what other medications were the patients taking? What's their medical history? What was the sequence of events? So what was the time to onset if possible, if we have that information between the patient taking the drug and them reporting the side effect, what the clinical course of the side effect was, so did the patient recover? Was any adjustment made to the the, the dosing or any treatments given? And so all that gets written up, we then decide what other information do we need to know?And then there's a feedback loop to go and ask the reporter if they'll provide additional information. Usually we ask for more information on more serious adverse events. We don't wanna overburden the reporters. Now reporters in clinical trials, so physicians involved in those, they're legally obliged to help with that process. Spontaneous reporters that we refer to, which is just where any healthcare professional or consumer contacts, the company, that's a voluntary reporting system, so we can ask them for additional information, they don't have to provide it, but we have to ask the questions anyway. So the information gets pulled together. It then goes, usually goes through a medical review, so we have kind of scientists pulling the data together. And then we have physicians reviewing the case, making sure it makes medical sense. And then depending on the seriousness of the case and other attributes, that case might have to be reported out to regulators worldwide.And a lot of the reports which are serious, have to be reported out within 15 days of what we call day zero, which is the first day anyone in the company became aware of the report. Parmvir: Mm-hmm. David: But to give you an idea, the large pharma companies are dealing with potentially tens of thousands of reports a week that are coming in on all of their products. So these are vast systems that are set up and they have to be set up to be able to meet all of the regulatory requirements in terms of timelines, for reporting. So the data's coming in, the expedited reports are going out in the format that the regulators require. We also have to pull together what we call aggregate reports. So these aggregated analyses of data over time for newer drugs, for example, those are submitted in Europe every six months. And then over time as the drug gets older, the gap between reports gets longer. And then also we're doing something, what we call signal section, which is where we are analyzing the data. And we're looking for trends in the data. Where we think we've got patterns we're starting to then look into researching those patterns a little bit more, you know, if we start to see, for example that I don't know that we are getting what appears to be a disproportionate number of nose bleeds, let's say, in a patient cohort, we would, you know, do background research on, well, you know, is there a plausible biological mechanism that we know about through the development of the drug? Was there stuff seen in the animal studies or even the human studies that might indicate that there's a, there's a root cause here.We'll look into confounding effects. Are all these patients on other drugs, which actually are likely causing that? And yeah, so kind of an appraisal is done: what's going on? Is it likely to be caused by something else? And if not, you know, we, keep on looking and those conversations then have to be shared with the regulatory authorities.And over time, what you'll see is the labeling of the product, the professional labeling which in Europe, including the UK, is the SMPC, the summary of product characteristics, which is a bit like the instruction manual for the product, which is available to healthcare professionals and the simplified version of that PIL those little leaflets you find inside of packs, those eventually get revised on an ongoing basis to accommodate the new knowledge that we are gaining on the side effect profile of the drug. So this is an ongoing process and it happens throughout the entire lifetime of the, of the drug. Parmvir: But yeah, so here's a subject that no one's talked about for a little while. COVID 19 David: mm-hmm Parmvir: [laughs] Obviously I know there's probably a collective groan from people listening right now, but it seems like a relevant subject, given the conversations around safety that people are having with regard to the vaccine. So do you know if there's been like a major uptick in these reports by individuals, of side effects from the vaccines, or do you take account of the fact that so many billions of people essentially at this point have received at least one shot of the vaccine versus how many reports you get coming in?David: Yeah. So this is one of the big challenges, and one of the things I should have said about drugs like vaccines is because they're given to such vast numbers of people, it becomes a particular challenge to differentiate between things which are being caused potentially by the vaccine and other things, which unfortunately are just bad luck of being a human being.And by that, I mean, so years ago when I was doing one of the academic courses we were being taught about the vast amounts of research that had to be done in terms of epidemiology before the HPV vaccines were released. So these vaccines were being released for use in teenage girls, and at the time it was felt that there was perhaps an insufficient understanding of the general health of that population, including things like what is the probability of a freak occurrence that a teenage girl is going to have a stroke or something like that? Things which we think of as of course, they're exceptionally rare, but they do happen.Parmvir: Mm-hmm David: and I'm talking about in untreated populations. Parmvir: Yep. David: But of course, you know, some of these patients are also on birth control and things like that, that also have other risk factors associated with them so my understanding is before the HPV vaccines were released, a huge amount of epidemiology research was done so that when the new vaccines were released, we knew that we would expect, and I'm just gonna make up a number here that, you know, one in 500,000 teenage girls would have, I don't know, some kind of fatal event which would just naturally occur, you know, even without them having the vaccine. And so that's similar for other vaccine rollouts as well. There has to be a good understanding of the background events of other things that, people will have happen to them, which have nothing to do with the medicine that you are giving.So, you know, that data is kept available and kept an eye on by the regulatory authorities and also the pharma companies. We don't have background rates for everything, so being prepared for what might come and then, you know, there perhaps isn't so much panic when the first case comes in of a patient that has one of these catastrophic events but if you start to see more than that, that's when you start to perhaps get more interested in: is this really being caused by the vaccine or the drug of interest. So, yeah, a lot of upfront work has to be done before you even put the drug out there. I mean, in terms of the COVID vaccines and the treatments, because of the high degree of public interest and scrutiny a lot of these drugs when they were first given and the vaccines were first given, so adverse events, side effects were tracked through post-authorization safety studies. So actually a lot of people, when they got their first doses, consented to have maybe a follow up call from an investigator who would ask them about various side effects that happened. So in addition to all of the natural spontaneous reporting that was coming in, there were very large cohorts of past study data coming in which is a robust way to look at these things. I know as well, there were legitimate questions about, you know, the COVID vaccines in particular were produced fairly quickly compared to the usual 10 to 15 years in development of, of a product. But you know, there are various reasons for this. So vaccines are perhaps one of the medicines where it's more possible to template out the product and therefore switch out components. But they still have a product which is similar to other products that have previously been used. But also, the COVID era in terms of vaccine development and treatment development was, in my opinion at least a completely unique event in terms of drug development so far. If you think of drug development as a kind of universe, or I'm gonna use some wonky analogies here, but let's say as galaxies, which have solar systems within them that have planets within them.So if you think of the galaxy of drug development you have all of these different stakeholders involved. You have the pharmaceutical companies and biotech companies and the service companies that support them, that's one area. You have the regulatory authorities but you have many other stakeholders.You have patients, of course they're the most important. For chronic diseases you might have patient advocacy groups. But also, you know, you guys are part of this universe as well, because you are the ones doing basic research, which is the foundation on which all, you know, all of this is, is ultimately built. So you have universities and other research organizations. You have the funding bodies that sit behind those that decide where the research money goes. And then out the other end of the process you have ethics committees that are involved in approving clinical trials. You have payers. So these are the organizations that ultimately pay for medicinal products in the UK, for example, that's the NHS. Parmvir: Yep. David: In the US, that would be insurance companies. Parmvir: Yeah. David: You have many other stakeholders. So you have obviously healthcare professionals at the end of the day, new drugs have to be woven into the fabric of medicine. And so you have to bring HCPs along with you. There are the learning bodies as well in relation to HCPs, the kind of professional bodies.So that's really at a kind of galaxy level, these are all the different solar systems. And then within them, if you look at the pharmaceutical biotechnology and service provider solar system, within those you have an incredibly complicated set of different skills departments, functions, you have the functions that are doing discovery.So these are the early days of, development where, you know, biologists and chemists are working out, you know, what are the new therapeutic targets we can look at? Then you have the clinical development division. You have the patent divisions, you have the regulatory affairs functions. You have the pharmacovigilance functions. You have the medical affairs functions, you have the medical information functions [Parmvir cackles]. There are, and I'm going to miss out many, many. You have the, the bio stats folks, you have the medical writers. And then of course you have the manufacturing, which is in itself a completely different, you know, specialized world.So yeah, you're dealing with a very complicated process with lots of things which are interlinked. But for me, if you think of all these things, like if you use layout or different compass, let's say, and I'm talking about the compass you use to check direction, not the ones you used to draw circles [Parmvir laughs] and if you scatter them all out they'll all be pointing at different directions. You know, all of these different entities have their own priorities. Because of course the industry as a whole is developing many different medicinal products for different reasons. I think when COVID came along, it was like drawing a magnet across the top of all those compasses and it got all the needles to point in the same direction.So you had governments who had a clear incentive to try and support the development of treatments. So you had governments putting up money, which was perhaps slightly unusual. They were putting money into basic research, such as the type of stuff that you guys do. They were putting money into diagnostics, which are critical for things like COVID.They were putting money into the development of vaccines and into treatments. And then of course, you know, you have the pharma companies where there was a scramble to try and develop something, to help humanity in its hour of need. You had the regulators with a lot of focus on them you know, and everyone watching their, every move and trying to ensure that you know, as many processes that often might take months, or perhaps even years were made as efficient as possible.Parmvir: Mm-hmm David: And it was a unique point in time because everyone was lined up with the same objective. So it meant, for example, that, you know, parts of the industry, which are normally a nine to five job, became a 24/7 job. Parmvir: Yeah. David: For a short period of time.And there was a huge amount of collaboration, which happened between the different stakeholder groups, you know regulatory authorities offered perhaps free scientific advice to companies that were developing this stuff. They met very regularly with companies that were in development. They gave a lot of advice as to what their expectations were when the data was received by them. They shortened some administrative pathways let's say which usually take a lot of time. They prioritized resource. So there's resource specifically waiting for this data to come in. And so, yeah, a lot of normal processes were adapted so that things could be done as efficiently as possible.And the outcome was that, you know, these drugs went through the entire process in a much more efficient way than would usually be encountered. I think another thing as well is with things like vaccines, the side effects that we anticipate to see, including the rare unusual ones ordinarily these manifest within, you know, days or weeks.It's not something that usually we anticipate things to occur years later. So there was that aspect too, but yeah, it was a, it was a unique time. Parmvir: Yeah. And actually this is a good throwback to Dr. Carina Rodriguez's podcast because she ran one of the clinical trials for the vaccine in children at USF where I work.David: Oh, fascinating. Parmvir: Yeah, so she talked about some of the things that you mentioned as well. David: I should say I was not involved sadly in any of the COVID vaccine development, but you know, it was fascinating to watch and actually to see my profession become a talking point in the news every day. Parmvir: Yes. David: It was very interesting to see all of this play out.Parmvir: Yeah. So actually, that's probably a good point to pause and ask you, what do you actually do? David: Okay. So [everyone laughs]. So as I've kind of indicated the process of pulling in adverse event data of coding it, which is the term we use for tidying up all of the data, putting it into a safety database, writing those narratives, getting the medical review, getting the important cases out the other end to the regulators, writing the reports, doing the signal section.These are very complicated processes and every company will develop them slightly differently. You know, small biotech companies, they might only have one product. It might only be approved in one or two countries. A top five pharma company will have hundreds of products authorized in many countries around the world. But all of these processes are put together in compliance with extremely strict regulations. Regulations that as I said exist in almost every country in the world and actually the regulations kind of cross over in the sense of, if you have a product that's authorized for marketing in the UK and the US, for example you know, the UK requires you to collect all the data and analyze it as does the US.They also require you to collect the data from each other's territories so companies are in the middle of the very complicated regulatory framework, which is a little bit different in each country, but fortunately is harmonized through some international bodies and international terminology. But building pharmacovigilance systems is complicated and it has to be done right. Firstly, for the obvious reason that we want to protect patients it's in no one's interest that that that patients are not protected. But also, you know, the penalties for not complying with these complex regulatory requirements are severe. And so my job really, as a, let's say senior leader within a pharmacovigilance department is to make sure that we build the right structures.And for these companies that we that we keep an eye out on all the areas, which are potential challenges and that companies are being compliant with the legislation to which we're all held. And so, so yeah, so building pharmacovigilance systems, I think is the simplest way I can describe it.Parmvir: It sounds pretty heavy and pretty complicated. David: Yeah. I mean, if you look at the larger pharma companies, if you add up all of the resource that they put into pharmacovigilance that they're legally required to put into pharmacovigilance, to service the needs of their products. A lot of things are outsourced these days, if you the count everything that comes from the outsourcing organizations as well, the big pharma companies have thousands of people like me involved in the processing and analysis of this data. So it is a big area, and that is all we do. You know, we are not involved in any other aspect of the drug. Not involved in the sales and marketing, for example, with the product, that's almost the complete opposite side of the company to us, all we do is you know, work in this very professionalized, very standardized discipline, which is pharmacovigilance. Parmvir: So David has a couple of questions. So first one should be relatively quick, which is that, is there a regulatory authority that is the gold standard? David: [David laughs] This is a very politically sensitive one.There are certainly some regulatory authorities who, particularly in some of the larger markets who are let's say more prominent. So examples would be the US FDA, the food and drug administration that is the drug regulatory authority for the United States. In the UK, we also have an extremely prominent regulator, the MHRA they're one of the oldest regulators, I believe in the world. So that's the UK medicines and healthcare products, regulatory agency. But you know, every country has its own regulator and whilst there are some who put themselves out there, perhaps as world leading regulators, there are just as many others that are doing the same important job for their countries. The European Union and European Economic Area has a slightly more complicated system because they have a coordinating regulatory authority, which is the European Medicines agency, the EMA, who many of you all have heard about in news reports, particularly during the COVID situation. But at a national level, you also have all of the national regulators who are working in tandem with the EMA. Parmvir: Okay. So this sounds quite different from, obviously it's very different from what you were doing during your PhD. David: Yes. Parmvir: He also wants to know, how did your PhD work, prepare you to do what you do now. David: If I could sum it up in one phrase, and this is a phrase which is overused, but I think in this case, it is really true: problem solving.Parmvir: Mm-hmm David: because it's interesting, you mentioned earlier that you and I we're almost engineers. Well, I went from becoming a physical engineer, at least in a lab environment to a process engineer. And, you know, I always used to think very naively when I was doing the basic research with you, I used to think, look, we are solving problems that no one knows the answer to. This must be the hardest job in the world. [Parmvir laughs] We're not solving manmade problems. Manmade problems must be so easy to solve. But no manmade problems [Parmvir laughs] are also particularly challenging. And when I say manmade problems, you know, I'm not talking about problems that someone is deliberately created, it's just, you know, logistical challenges, and just the challenges caused by working in, you know, different regulatory envionments with different sets of requirements and how to build processes that meet all of the requirements at the same time. And react to events, of course, because it might well be that you've had a product that has been ticking along nicely for a long time. And then suddenly there is a safety concern with the product. And if that safety concern is in the public domain, you will be deluged with reports in relation to that product called stimulated reporting. And you know, of course sometimes companies will be subject to class action lawsuits particularly in the US. So they might also receive large volumes of reports all in one go. All of those reports have to meet the same legal timelines, but now suddenly you've got 10,000 reports landed on your desk. Each one takes four hours to process and they're all due to the regulators in 15 days. So yeah, it is challenging working in a hyper regulated environment. Parmvir: Essentially these are problems that come about because we are humans. David: Exactly. Yeah. Parmvir: And we have to somehow live together. David: Yeah. Parmvir: So I had a couple of questions from my little sister and these might not be directly related to your work, but they are related to the fact that you work within an environment that involves clinical trials and patients and so on.And so Sukhy wants to know are side effects from drugs, usually the same for healthy people versus patients. David: This is a great question and cause me a little bit of head scratching. I think, I mean, the answer is it depends, I think by and large. Yes. But there will be some exceptions and those exceptions include things like some of the oncology treatments, because obviously there is an interaction often between the drug and the tumor, for example, so in a healthy person you can't emulate that because there is no tumor. So an example would be a phenomenon called tumorlysis syndrome which can only occur when there's a tumor to react to the particular drug. But by and large, yes, we extrapolate safety data from healthy individuals initially, which is why the earlier phases of studies are done often in healthy volunteers with some exceptions. But yeah. Then when we move on to phase two and then phase three, phase two and three are conducted in patients that have the indication of interest, I have the disease that we're trying to treat.Parmvir: So another question she had: how do you know people who are not healthy will be able to tolerate the drugs given that initially that they're tested on healthy people?David: So the first thing I would say is I'm not an expert in the design of clinical trials, but as I said, as you go through phase one which are the trials that are normally on healthy patients, you actually start out with a tiny, tiny dose. So you have an idea of dosing from your animal studies, but the data isn't always transferrable. But you take the maximum tolerable dose in animals, including in the most sensitive animals. And you then cut that by huge factor by perhaps 500 fold. Parmvir: Right. David: So you start out with a tiny amount and then you escalate up the doses to see how the patients are tolerating the drug, not the patients subject, I should say. So these are healthy volunteers usually. Parmvir: Yep. David: So that's phase one, but yeah, then of course, when you go into phase two, you're dealing with a different patient population. I don't know exactly how that's always done, but of course, you know, trials are put together by experts in the field. And they involve, you clinicians whose expertise is this particular area of medicine.Parmvir: Yeah. David: And of course it's not just the physicians at the pharmaceutical company and the biopharma company and the scientists, I should say as well. Also, this stuff is going to regulatory authorities, it's going to ethics committees, all of whom will have their own areas of expertise. So, you know, protocols are designed around the patient and to ensure the patients are not put at unnecessary risk.Parmvir: Ah, sometimes David sends me one of those questions that really makes me giggle. And this is if regulations are so important and onerous, how do I start my own biotech in the garage? David: [David laughs] Well, it's interesting, you know, companies don't necessarily have to be that big themselves to get started, but what they will need is a lot of help.Parmvir: Yeah. David: So what you'll see these days is you know, new biotechs starting up. But they rely very heavily on outsourcing. So they will partner with service providers with contract research organizations, with contract manufacturing organizations, all sorts of other parties that have the expertise that perhaps they aren't able to pull together themselves.But yeah, there are some companies out there, particularly smaller companies in earlier development that are, you know, pretty small might have 20 people in the company. Parmvir: Yeah. David: But they will need to rely on the help of many others, because going back to the kind of universe description that I gave, you know, there are so many specialized areas that you need to have covered in order to pull together everything you need, both to run a clinical trial. and also to submit a marketing authorization application. And then also keep your product compliant with all of the legal requirements that are out there.Parmvir: It's a lot.David: It is a lot, and you know this is why drug development is so costly because it needs a truly vast number of specialists involved. And, you know, quite a lot of physicians as well. And also, you know, most drugs that enter drug development don't make it all the way through the other end, so the end costs of medicinal products also have to cover the cost of the drugs that didn't make it.And plus companies only have a certain period of exclusivity before their drug becomes generic, i.e., other companies can start making it. Parmvir: So this is purely from a personal perspective, from your point of view: what do you think about the fact that obviously you have these companies who have put so much money developing these things, which were designed to treat a global pandemic. And yet we found that for example, like entire continents, like Africa still don't have a lot of people vaccinated against COVID 19, and those companies will refuse to open up the patents to allow them to be able to get people to stay healthy. David: Yeah, it's an area that really I'm not really sufficiently qualified to talk on. And I'm not just saying that, you know, through not wanting to put my foot in my mouth, but particularly with some of the vaccine technologies that were used, they were not simple medicines to manufacture. So not simple to manufacture, not simple to store, not simple to distribute. And sometimes I guess, it is perhaps a legitimate concern of a company that if other companies start making their same drug to a lower quality, that can have ramifications elsewhere. Now I'm not saying that that was the reason behind some of what you mentioned. Now there was a vaccine that was developed the UK vaccine which was specifically developed from the outset to be made available in developing world countries, let's say, and specifically to be made available at cost. And even the way that product was designed, it can be manufactured and stored at fridge temperature Parmvir: mm-hmm, which is a big deal. David: Exactly. It is a big deal, you know, those are all very important components to consider. A vaccine that could be used in those environments. But even, I remember because I vacuumed up all of the documentaries I think on television, Netflix, everywhere else about all of the challenges that were being faced. And, you know, there were even things that you just wouldn't think about, which was, you know, because the mRNA vaccines had to be stored at -80 [degrees Celsius], there wasn't enough minus 80 freezers in the developed countries, let alone figuring out how to develop and ship these to other countries with different climatic conditions.And so you even had the manufacturers of that type of equipment, having to up their game and suddenly churn out much more equipment than they previously had. So, yeah, there's no simple answer. I mean, historically there've been other challenges in the past with other types of drugs, such as the HIV medications. In the end access to those drugs was resolved through very careful dialogue between companies, regulators others. Access issues, I believe to those drugs, and again, this is just basically what I see on documentaries and other things; where are access problems these days, they're not in relation to the drug supply chain they're in relation to other things like people not wanting to come forward and receive treatment because of the stigma associated with things like that.Parmvir: So in short, do you enjoy your work? David: I do. I mean, I can honestly say that in my work every day is different. I'm very privileged in my job to support a number of different companies that are developing different products with a very wide variety of indications. And also, you know, just when you think you've seen it all worked with a wide variety of medicinal products, suddenly something completely new will come along. For example, we are now on the precipice of many commercial gene therapies coming out. Parmvir: Ooh. David: And you know, those products have some different considerations. Perhaps some of these interventions are irreversible Parmvir: mm-hmm.David: So, you know, what happens if patients do start developing something rare and unexpected. You have patients surviving a lot longer than was originally envisaged so, you know, are there other things which come about you know, as a result of the underlying disease that just no one had ever seen before. And yeah, many other types of technologies and the regulations are always having to evolve to take into account of these new therapies and the challenges associated with them.Parmvir: Well, it sounds like you will continue to live in interesting times. David: Yeah. I don't think I'm going anywhere anytime soon . Parmvir: Well, thank you so much for your time today, David. That was fantastic. And yeah, as I say, we kind of thought of you as soon as we started thinking about the safety surrounding things like COVID vaccines and knew that was your jam.So yes, we very much appreciate your time today. David: Okay. Thank you very much. [musical interlude]David: So I mentioned earlier that at an early point in my PhD, I switched to studying vascular endothelial cells that were harvested from pigs. So essentially these were pigs that were being slaughtered for the meat industry. And so I had to look through a phone book and identify an abattoir that I could go to and get the tissue that I needed to do my experiments so obviously this all had to start somewhere. So I put in a call to an abattoir in deepest, darkest Essex. And I gingerly made my way on the train to this place, which of course was in the middle of rural nowhere. And unfortunately the first day that I picked to go, it was snowing. Now we don't get vast amounts of snow in Southern England, but this was a decent sprinkling of snow. So I arrived in this quiet rural destination and I walked across various fields. I think I'd perhaps just got GPS on my phone, but it was very early days. And I was lost in fields of white in no time at all. So I ended up putting in a call to, the guys, to, come and pick me up, which they very kindly did. So then, you know, at that time I really didn't know what a coronary artery looked like so what I decided to do for that first trip was I just collected the fresh hearts that they were able to bring out the processing facility. So these were kind of warm pig hearts, freshly harvested from animals. I think I had three hearts or something like that. And so I had a large polystyrene box with me with some ice in it. And I think they were kind enough to give me the ice, as I put these hearts inside bags and put them in the box and then started making my way back to London. And of course, you know, this being a cold day, the heating was on, on the train, and so as I was sat on the train, in fact, I think it was when I got onto the tube, I suddenly became horrified that my polystyrene box was starting to leak water. And of course I knew, but no one else knew on the tube that within that water were bags, perhaps not secured, very tightly containing hearts and containing probably a fair amount of blood.And I suddenly started sweating that this puddle that was starting to pull around my polystyrene box on the floor of the tube would suddenly start to go pink and then red. And then before I knew it, I would be in serious trouble. So it was just one of those situations where the tube journey seemed to get longer and longer, and I was sweating more and more and then it got to the point where I felt that I couldn't wait any longer, so I kind of dashed outta the tube at the next station went up what was perhaps one of the longest escalators on the underground and managed to just get out the other side before I caused perhaps a fake terrorist incident or something like that. I was trying to think about how I would explain that I'd got three hearts in my polystyrene box and a set of scalpels bearing in mind that pig's hearts are very similar size to human hearts as well. So, yes, I managed just about to get to the lab. I clearly looked quite distressed, I suppose when I got back to the lab. So I started telling this story to my PhD supervisor, Dennis, and uh a retired professor that had come into the department, Don. And before too long, the two of them were crying with laughter at my story.So, um, so yeah, so that was my very first trip and yes, never, never forgotten.[musical outro]David: Our lab, when we first joined, it was quite old and a bit dog eared. And there was one particular chair in the office, which was, I mean, it was like a typical office swivel chair, but it had definitely seen better days and it was extremely uncomfortable. And when we had lab meetings, no one wanted to sit on this chair. And so Parmvir and I nicknamed it, Beelzebub's stool.

Die Firma "More Nutrition" gehört zu den bekanntesten Anbietern von Nahrungsergänzungsmitteln im Internet. Das Versprechen von Mitgründer Christian Wolf: Alle Produkte seien sinnvoll und evidenzbasiert. Egal ob zum Abnehmen, für besseren Schlaf oder gesündere Gelenke. Doch stimmt das wirklich? Für diesen Fall haben die Science Cops gemeinsam mit MedWatch recherchiert. Das Ergebnis dürfte More Nutrition nicht gefallen. Unsere Quellen: https://www.quarks.de/science-cops Von Jonathan Focke.

In episode 61, host and clinical educator Jon Wood discusses recent activity surrounding the FDA medical safety information and adverse event reporting program (MedWatch) for healthcare professionals and patients. He specifically addresses the medical device reports relating to endoscope reprocessing and patient infections. Earn a certificate of completion for this Podcast by visiting IAHCSMM's Online Learning System and competing the quiz. Earn CE Now    

ADHD MEDICATION & VIOLENCE is an episode designed to make parents aware of the dangerous effects of stimulant drugs for ADHD. In 2006, the FDA's ADHD psychiatric review team called for stronger warnings on ADHD drugs after a safety review found almost 1,000 case reports of psychosis (including hallucinations) or mania related to Adderall, Concerta, Ritalin and Strattera submitted to the agency by drug makers between January 1, 2000 and June 30, 2005. These symptoms came in children with “no identifiable risk factors, at usual doses of any of the drugs used to treat ADHD.” There was a “complete absence” of these ADHD medication side effects in children treated with dummy pills during clinical trials and in many children the symptoms stopped when the drugs were withdrawn and resumed when they were restarted. In addition to the case reports submitted by manufacturers, there were 560 reports of psychosis or mania submitted to the FDA via its MedWatch reporting system. It is estimated that only about 1% of adverse side effects are reported to the FDA. This suggests that over 100,000 children diagnosed with ADHD may have become psychotic or manic while taking ADHD drugs during this five- and-a-half year period. The same safety review reported “numerous postmarketing reports of aggression or violent behavior during drug therapy of ADHD.” In approximately 20% of the cases the behavior was considered life-threatening or required hospitalization. The majority of the reports of ADHD violent behavior were for children and adolescents, most of whom had “no specific risk factors for aggression or violent behavior.” According to the report, “a striking majority (80 to 90% overall) of patients … had no prior history of similar events.” Drug makers submitted over 1,400 reports of ADHD aggression or violent behavior, with over 700 additional cases reported to MedWatch. The FDA report establishes an unmistakable tie between ADHD medication and violence. In 2010, Thomas Moore, a senior scientist at the Institute for Safe Medical Practice (ISMP) and Joseph Glenmullen, a Clinical Instructor in Psychiatry at Harvard Medical School, published a joint study on prescription medication-induced violence, finding that 31 prescription medications are disproportionately linked to reports of violent behavior. In the study, Moore and Glenmullen extracted serious adverse event reports from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System, searching for any drugs with 200 or more case reports received from 2004 to 2009. They selected any reports that indicated homicide, homicidal ideation, physical assault, physical abuse or violence-related symptoms, and then used mathematical and statistical methods to identify drugs that were significantly more associated with those reports compared to other drugs. Out of 484 medications they evaluated, 31 (6%) were significantly more associated with violence. All but seven of the drugs were psychiatric drugs. The medications below were the most strongly associated with violent adverse events: Varenicline (Chantix, Fluoxetine (Prozac, Paroxetine (Paxil, Amphetamines, Mefoquine (Lariam, Atomoxetine (Strattera), Triazolam (Halcion), Fluvoxamine (Luvox), Venlafaxine (Effexor), Desvenlafaxine (Pristiq) Parents and the public have a right to know what psychiatric drugs do in the brain, the side effects of taking and withdrawing from these medications, and the medical basis — or lack thereof — behind the skyrocketing numbers of children being prescribed these drugs. Resources: https://www.baumhedlundlaw.com/medication-induced-violence/ https://www.druginjury.com/druginjurycom/2006/03/adderall_cardia.html https://journals.sagepub.com/doi/abs/10.1345/aph.1P172 For more information on this podcast, please visit www.adhdisover.com

The Beyond Clean GoldMind is a free innovative digital dictionary resource for Sterile Processing terms, featuring diverse voices from around the globe who provide definitions to the most common terms in our industry. Releasing 365 days a year, GoldMind is your daily dose of Sterile Processing education and insight to invest in yourself, your future, and the safety of your patient. It is a perfect addition to new technician on-boarding, certification studies, and educational programming in your facility. For more creative Sterile Processing education & resources, visit us at http://www.beyondclean.net #GoldMind #BeyondClean #DigitalDictionary #WordOfTheDay #Education #SterileProcessing #Voices #Network #Listen #Learn #ChangeTheWorld

Statsminister Mette Frederiksen overraskede i går ved at foreslå, at Danmark skal bruge borgernes sundhedsdata i byttehandel med medicinalvirksomheder for at få fordele i adgangen til vacciner. Men faktisk har danske sundhedsmyndigheder allerede forsøgt sig. Det oplyste Statens Seruminstituts direktør til mediet Medwatch i januar. Vi er nødt til at rense mere drikkevand. For selvom vi har været vant til at have nok så rent grundvand, så er forureningen med pesticidrester og deres nedbrydningsprodukter blevet for stort et problem i mange af landets kommuner. Så nu vil over halvdelen af dem rense vandet. Antallet af jobopslag stiger og rammer det højeste niveau siden finanskrisen. Vi undersøger, HVOR de nye jobs bliver skabt, og om de giver håb for de tusindvis af mennesker, der er blevet ledige under corona-krisen. Mette Vibe Utzon og Mathias Bay Lynggaard er dagens værter, Tine Møller Sørensen redigerer. www.dr.dk/orientering

Statsminister Mette Frederiksen overraskede i går ved at foreslå, at Danmark skal bruge borgernes sundhedsdata i byttehandel med medicinalvirksomheder for at få fordele i adgangen til vacciner. Men faktisk har danske sundhedsmyndigheder allerede forsøgt sig. Det oplyste Statens Seruminstituts direktør til mediet Medwatch i januar. Vi er nødt til at rense mere drikkevand. For selvom vi har været vant til at have nok så rent grundvand, så er forureningen med pesticidrester og deres nedbrydningsprodukter blevet for stort et problem i mange af landets kommuner. Så nu vil over halvdelen af dem rense vandet. Antallet af jobopslag stiger og rammer det højeste niveau siden finanskrisen. Vi undersøger, HVOR de nye jobs bliver skabt, og om de giver håb for de tusindvis af mennesker, der er blevet ledige under corona-krisen. Mette Vibe Utzon og Mathias Bay Lynggaard er dagens værter, Tine Møller Sørensen redigerer. www.dr.dk/orientering

On this week’s podcast: A change made by the US FDA to its MedWatch program that asks adverse event reporters whether a third party serviced a malfunctioning medical device went unnoticed by many in industry for nearly a year. We explain why, and tell how the servicer question will be helpful for manufacturers and the agency. Medtech Insight article addressing topics discussed in this episode: • Recent eMDR Change By FDA Asks Adverse Event Reporters About Third-Party Servicers https://medtech.pharmaintelligence.informa.com/MT142951/Recent-eMDR-Change-By-FDA-Asks-Adverse-Event-Reporters-About-Third-Party-Servicers

Nicola Kuhrt und Hinnerk Feldwisch-Drentrup von und zu medwatch | Dr. Julia Holl zur PACE-Studie | viele News und wieder ein Medizinmurks

The byzantine rules and procedures of multilateral institutions form the backdrop for China's global power play, following President Xi Jinping's 2018 call for China to “lead the reform of the global governance system with the concepts of fairness and justice.” As the US pulls back from its global obligations, there's increasing evidence that China is simply changing the rules inside these global bodies. In this episode, we explore whether China is influencing three international organizations: the U.N. Human Rights Council, the World Trade Organization, and the World Health Organization. To ask whether Xi’s vision of a new global order is being realized, Louisa and Graeme are joined by Sophie Richardson, the China director at Human Rights Watch, trade expert Weihuan Zhou from the University of NSW’s law school, and freelance journalist Hinnerk Feldwisch-Drentrup who is the co-founder of MedWatch. Credit: UN Photo / Yun ZhaoCaption: Secretary-General Meets with President of China. Secretary-General António Guterres (left) meets with Xi Jinping, President of the People's Republic of China, in Great Hall of the People during the 2nd Belt and Road Forum in Beijing, China.26 April 2019See omnystudio.com/listener for privacy information.

Bevor Menschen heute einen Arzttermin machen, fragen die meisten erstmal Dr. Google. Doch nicht immer finden sie dort die richtigen Antworten. Das Netz ist voll von unseriösen Heilsversprechen und betrügerischen Seiten, die mit der Angst um die eigene Gesundheit ein Geschäft machen. Doch wer schützt den Verbraucher vor den Scharlatanen? Die Medizinjournalistin Nicola Kuhrt und ihr Kollege Hinnerk Feldwisch-Drentrup ärgerten sich, dass es im Netz kaum Kontrollmechanismen gibt - und gründeten den gemeinnützigen Blog MedWatch. Dort klären sie ihre Leser in tagesaktuellen Nachrichten, Interviews und Reportagen über Gesundheitsthemen und Fake-Seiten auf. Nicola Kuhrt findet: "Als Medizinjournalistin hat man eine besondere Verantwortung. Berichtet man doch über Themen, die die Gesundheit des Einzelnen berühren." Ihre Leser bestärken sie darin. Neulich fragte jemand auf Twitter zu einem Medikament: "Kann das wirken?" Ein Nutzer antwortete: "Frag doch medwatch.de." Für Nicola Kuhrt eine der schönsten Bestätigungen für ihre Arbeit. Bestätigung bekam sie auch von uns: Im Juni erhielt sie für ihre Arbeit den EMOTION.award 2019 in der Katergorie "Soziale Werte". Im dieser Podcast-Folge erfahrt ihr wie Nicola vom Film- zum Medizinjournalismus kam,warum sie MedWatch gegründet hat,wie Nicola und Hinnerk ihre Geschichten recherchieren,wie Nicola den Blog mit ihrer freien Arbeit und der Familie arrangiert,was sie nachträglich anders machen würde,wie ihr den Blog unterstützen könnt Wir wünschen euch viel Spaß beim Hören!

MedWatch-redaktionen ser tilbage på ugen, der gik. Albert Rønning-Andersson, Ulrich Quistgaard og Kevin Grønnemann er i studiet.

Interview mit Nicola Kuhrt von MedWatch, dem Blog, der das Netz nach gefährlichen und unseriösen Heilungsversprechen scannt. Wir sprechen über Filme, die mit Emotionen manipulieren und warum im Zeitalter von Chemtrails und Pizzagate Wissenschaft und Forschung immer wieder neu verteidigt werden müssen.

MedWatch-redaktionen ser tilbage på ugen, der gik, hvor Leo Pharma og Lundbeck løb med noget af opmærksomheden. Elizabeth Mønsted Johansen, Albert Rønning-Andersson og Mikkel Aabenhus Hemmingsen er i studiet.

MedWatch-redaktionen ser tilbage på ugen, der gik, der bød på regnskaber, kursrekorder og en helt ny dansk spiller på migrænemarkedet. Elizabeth Mønsted Johansen, Kevin Grønnemann og Ulrich Quistgaard er i studiet.

MedWatch-redaktionen ser tilbage på ugen, der gik, hvor især regnskaber og coronavirus løb med opmærksomheden. Elizabeth Mønsted Johansen, Albert Rønning-Andersson og Mikkel Aabenhus Hemmingsen er i studiet.

MedWatch-redaktionen ser tilbage på ugen, der gik. Kevin Grønnemann, Ulrich Quistgaard og Mikkel Aabenhus Hemmingsen er i studiet.

I en række artikler har MedWatch taget et blik på Enochian Biosciences, der har en milliardvurdering på grund af en præklinisk, potentiel hiv-kur og en forsker, som direktionen gang på gang har udråbt til et geni. I denne podcast fortæller Kevin Grønnemann og Peter Thomsen om artiklerne.

MedWatch-redaktionen ser tilbage på ugen, der gik. Kevin Grønnemann, Albert Rønning-Andersson og Mikkel Aabenhus Hemmingsen er i studiet.

This week András is back and we start by philosophizing a bit about what a new decade really means and look forward to a few nice skeptics meetings coming up. We also talk about the future for Golden Rice and why it is so important despite what Greenpeace and EU politicians think. From history we hear about the so-called ‘psychic' Doris Stokes who was born this week in 1920 and Pontus Pokes the Pope for telling others to show restraint while he himself lost his temper just a few days ago. Should he be the one who negotiate peace in the Middle East? We think not. In the News this week: MedWatch.de turns into full online magazine, the people behind the Manifesto Against Pseudotherapies are getting sued by homeopaths and Prince William starts the ‘Earthshot Prize' to fight the climate crisis. We look back on a decade of Edzard Ernst, praise Hayley Stevens for continuing to spread light over ghost hunting and look forward to Natalie Grams new book coming out in February. Also, the ‘El Esceptico' magazine has recently examined the pharmaceutical industry in an excellent way. We end by handing another Really Right to the Daily Mail(!), this time for taking a critical look at the New Year's diet recommendations. Enjoy! Segments: Intro; Greetings; This Week; Pontus Pokes the Pope; News; Really Right; Quote and Farewell; Outro; Out-takes Events Calendar: http://theesp.eu/events_in_europe

MedWatch-redaktionen ser tilbage på året, der gik i dansk life science. Kevin Grønnemann, Elizabeth Mønsted Johansen og Albert Rønning-Andersson er i studiet. Mikkel Aabenhus Hemmingsen er vært.

MedWatch-redaktionen taler om medicoleverandøren Mediq, der skifter topchef, biotekselskabet Monta Biosciences, der har fået 40 mio. kr., og hjemsendelsen af direktøren for Seruminstituttet, hvor en skandale kan være under opsejling.

MedWatch-redaktionen taler om biotekselskabet Orphazyme, Sanofis exit fra diabetesmarkedet og Leo Pharmas nye studieresultater, der giver håb om at kunne konkurrere med blockbustermidlet Dupixent.

MedWatch-redaktionen taler om den kaotiske fyring af Chemometecs topchef Michael Eising, et nyt projekt om virtuelle kliniske forsøg og om de udenlandske direktører, der på kort tid er fordoblet i de børsnoterede life science-selskaber fra Danmark.

In this week's episode we talk about ‘kwakzalverij', the Pope's new Olympic ambitions (and female football team) and other papal adventures. There are steep fines coming for German vaccination dodgers and a study finds that absence of evidence is evidence on non-sense. MedWatch gets the Carl Sagan award, there is another example of vegan parents that jeopardize the lives of their children and French authorities are stepping up the fight against homeopathy (Boiron Is not happy). We also look into whether the code of the Voynich manuscript really has been broken and how another populist right wing party tries to score points by questioning climate change. We end with awarding a Really Right to a football player for not wanting to take advantage of how hard it really is to understand the odds of gambling. Segments: Intro; Greetings; This Week in Skepticism; Pontus Pokes the Pope; News; Really Right; Quote; Outro; Out-takes

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Jørgen Rudbeck om de vigtigste nyheder fra life science-området i uge 11 og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i uge 10 og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Morten Olsen om de vigtigste nyheder fra life science-området i uge 9 og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i uge 8 og ser frem mod den kommende uges nyheder.

Journalist Kevin Grønnemann, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i uge 7 og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i uge 5 og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i uge 5 og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Morten Olsen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Morten Olsen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

How to look up side effects for headache and migraine medicines In this episode, Dr. Edmund Messina, a Board certified neurologist and headache specialist follows up on how to look up headache (including migraine) medicine side effects and how to interpret your findings. He defines side effects vs. adverse effects and how to understand the severity or harmlessness of what is published. He talks about how side effects are dependent on the individual person as well as other factors such as other medications, supplements and general health. Not everyone gets a side effect, most people get no side effects from most meds.   Knowing that a medication MAY cause a side effect is not the reason to not try it. Being aware of side effects should be more of a guideline... it's not a call to action so you are on the alert for them. Just because a side effect has been reported in someone else, it does not mean that everyone gets it. Logically, it would be helpful to know what percentage of people have had problems with a medication, and we'll get to that soon. He discusses adverse effects and offers a website to check them, the FDA Adverse Event Reporting System (FAERS) Public Dashboard. He talks about how to use the https://www.fda.gov/drugs/guidancecomplianceregulatoryinformation/surveillance/adversedrugeffects/ucm070093.htm if needed. He reviews how sometimes, widely popular medications have been taken off the market because of lethal outcomes. For people concerned about safety, he discusses Medwatch (https://www.fda.gov/safety/medwatch/ ) , as well as Black Box warnings. For those who simply want to see how probable side effects can be for a specific medication, he discusses Daily Med ( https://dailymed.nlm.nih.gov/dailymed/ ).   He emphasizes that each patient needs to be considered as an individual and that generalities are not helpful.   As always, he urges headache patients to never give up, there is always something to help them. Dr. Messina is certified in Neurology by the American Board of Psychiatry and Neurology and in Headache Medicine by the UCNS. Details of his credentials are found at https://www.michiganheadache.com/emessina.asp . Disclaimer: Remember, to listen to the disclaimer at the beginning of each podcast and the one on the The Headache Situation website (www.theheadachesituation.com). Our podcasts are intended to be informational and educational and not intended to replace your doctor, physicians assistant or nurse practitioner. Do not make any health decisions based on the information discussed here, talk to your doctor.

Jahresausklang mit den Evidenz-Geschichten, MedWatch und "unserer" Frau beim Ärzteblatt

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Morten Olsen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Morten Olsen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Lunapharm & Co | Arzneimittelaufsicht | PsSG | BARMER Pflegereport | Nicht-kommerzielle Studien

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Markante direktørexit, fyringer i Novo Nordisk - og næste uges vigtigste nyheder. Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Morten Olsen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Redaktør Mikkel Aabenhus Hemmingsen, MedWatch, taler med Michael Ørtz Christiansen om de vigtigste nyheder fra life science-området i ugen, der gik, og ser frem mod den kommende uges nyheder.

Hey Medicare Nation! I have a special show for you today. The FDA has issued a "Voluntary Recall" on Westminster Pharmaceuticals of all lots of their Levothyroxine and Liothyronine (Thyroid Tablets). Westminster Pharmaceuticals, LLC, which has its Corporate HQ in Tampa, Florida, is voluntarily recalling all lots, within the expiration date, of Levo-thyroxine and Lio-thyronine (Thyroid Tablets) dosages of 15 mg, 30 mg, 60 mg, 90 mg, & 120 mg up to the wholesale level. These products are being recalled by Westminster Pharmaceuticals as a precaution, because they were manufactured using active pharmaceutical ingredients that were sourced, prior to the FDA’s “Import Alert”  of Sichuan Friendly Pharmaceutical Co., Ltd., which is out of China.   The Recall comes as a result of a 2017 inspection where deficiencies were found with “Current Good Manufacturing Practices” (cGMP). Substandard cGMP practices…..could represent……the possibility of risk….. being introduced into the manufacturing process. To date, Westminster Pharmaceuticals has not received any reports of adverse events related to this product. Levothyroxine and Liothyronine (thyroid tablets, USP) for oral use is a natural preparation derived from porcine thyroid glands. Thyroid tablets contain both tetra-io-do-thyronine sodium (T4 levothyroxine) and lio-thy-ronine sodium (T3 liothyronine). Levothyroxine and Liothyronine tablets (thyroid tablets, USP) are indicated as replacement or  supplemental therapy in patients with hypothyroidism. Because these products may be used in the treatment of serious medical conditions, patients taking the recalled medicines should continue taking their medicine until they have a replacement product. According to the U.S. Food & Drug Administration Report..... [8/17/2018] FDA is alerting active pharmaceutical ingredient (API) repackagers and distributors, finished drug manufacturers, and compounders that Sichuan Friendly Pharmaceutical Co. Limited, China, is recalling certain lots of porcine thyroid API due to inconsistent quality of the API. FDA recommends that manufacturers and compounders not use Sichuan Friendly’s porcine thyroid API received since August 2015. This thyroid API comes from porcine (pig) thyroid glands and is used to make a non-FDA approved  drug product, composed of levothyroxine and liothyronine, to treat hypothyroidism (underactive thyroid). FDA laboratory testing confirmed the Sichuan Friendly API has inconsistent levels of the active ingredients – levothyroxine and liothyronine – and should not be used to manufacture or compound drugs for patient use. Risks associated with over or under treatment of hypothyroidism could result in permanent or life-threatening adverse health consequences. These lots were distributed nationwide in the USA to Westminster’s direct accounts. These lots were distributed nationwide in the USA  NDC Product Lot Expiration 69367-159-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 15mg X 100ct 15918VP03 2/29/2020 15918VP02 2/29/2020 15918VP01 2/29/2020 15918007 3/31/2020 15918006 3/31/2020 15918005 2/29/2020 15918004 12/31/2019 15918003 12/31/2019 15918002 12/31/2019 15918001 12/31/2019 15917VP03 10/31/2019 15917VP02 10/31/2019 15917VP01 10/31/2019 69367-155-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 30mg X 100ct 15517VP01 8/31/2019 15517VP02 8/31/2019 15517VP03 8/31/2019 15518001 12/31/2019 15518002 3/31/2020 69367-156-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 60mg X 100ct 15618011 3/31/2020 15618009 2/29/2020 15618008 2/29/2020 15618004 12/31/2019 15618002 12/31/2019 15617VP06 11/30/2019 15617VP05 11/30/2019 15617VP04 12/31/2019 15617VP03 7/31/2019 15617VP01 7/31/2019 15617VP-02 7/31/2019 69367-157-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 90mg X 100ct 15717VP-01 7/31/2019 15717VP-02 7/31/2019 15717VP-03 7/31/2019 15718004 3/31/2020 15717002 12/31/2019 69367-158-04 Levothyroxine and Liothyronine (Thyroid Tablets, USP) 120mg X 100ct 15817VP-01 9/30/2019 15817VP-02 9/30/2019 15817VP-03 9/30/2019 15818001 3/31/2020 Westminster is notifying its direct accounts by email and by phone to immediately discontinue distribution of the product being recalled. The FDA Advises Consumers who have the recalled products, should not discontinue use before contacting their physician for further guidance. There are several manufacturers who make “generic” Levothyroxine and Liothyronine (thyroid tablets) that your doctor can give you a new prescription for.  Call the Pharmacy where you receive your Levothyroxine or Liothyronine, and ask the pharmacist who the manufacturer of their supply is. They should be able to easily tell you that. Customers and patients with medical-related questions, information about an adverse event or other questions about the Westminster’s product’s being recalled……. should contact Westminster’s Regulatory Affairs department by phone at: 888-354-9939 ….. Live calls are received Monday-Friday, 9:00AM - 5:00PM EST with voicemail available 24 hours/day, 7 days/week or you can send an email to  recalls@wprx.com. Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online…..by regular mail……or by fax. To Complete and submit the report Online…....just “click” on the link & it will take you directly to the FDA MedWatch Page. FDA Med Watch Page   If you’d like to report Adverse Reactions or quality problems by Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm  Med Watch Reporting Form or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form……or…….submit by Fax to 1-800-FDA- 0178   It’s almost the Annual Enrollment Period! Beginning Monday, October 15th through Friday, December 7th, many of you will be able to switch Medicare Advantage Plans, Switch Medicare Prescription Drug Plans or return to Original Medicare, with the majority of you having NEW effective dates of January 1, 2019. There are MANY Changes coming to Medicare for 2019, so I will be busy Posting Changes for you Starting the Week of October 1st. Medicare Nation, will be going back to a “weekly” episode during the Annual Enrollment Period, so that I can bring to you the most up-to-date information I can. Remember, I am here to answer ANY Medicare question you have, as long as I can answer your question in ONE paragraph. If I need to “research” anything or…..if it takes me more than one paragraph to answer your question, I will advise you that you can contact me to help you with your Medicare needs by hiring me to “consult” with you about your Medicare needs. Many of you contacted me last Medicare Annual Enrollment Period for consultations and I am here again to assist you or your parent’s Medicare Questions or concerns. Need help choosing a Medicare Advantage Plan or Prescription Drug Plan where you live? I can help you with that. Need help comparing your employer insurance plan benefits to a Medicare plan? I can help you with that too. Contact me by email at Support@TheMedicareNation.com or call the toll free number 855-855-7266 and tell me how I can help you with your Medicare Needs.   If you like Medicare Nation, I’d love for you to give Medicare Nation an honest Rating and Review on Apple Podcasts.   How to leave an iTunes rating or review for a podcast from your iPhone or iPad Launch Apple's Podcast Tap the Search Enter Medicare Nation in the search field. Tap the blue Searchkey at the bottom right. Tap the album art for Medicare Nation. Tap the Reviews Tap Write a Reviewat the bottom. Enter your iTunes passwordto login. Tap the Starsto leave a rating. Enter title text and content to leave a review. Tap Send.   If you have an ANDROID phone…..open up your “Stitcher” App or Download the Stitcher App from your Google Play App. OR……just go to ……. subscribe on Android.com When the page opens, just type in Medicare Nation into the field. Hit enter and voila! Click on the Medicare Nation Full LOGO and “click” Subscribe on Android. That’s it! Folks You now will receive my up to date Medicare Weekly episode to get you through the AEP   Thanks for listening to Medicare Nation! I appreciate it. Until next time….I want each of you to have a …..Happy, Healthy and Prosperous Week!      

The FDA announced that it is requiring a new class warning and other safety measures for all gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (or MRI) concerning gadolinium remaining in patients’ bodies, including the brain, for months to years after receiving these drugs. Report side effects involving GBCAs to FDA’s MedWatch program at www.fda.gov/medwatch. A link to the full communication detailing specific information for health care professionals and a list of FDA approved GBCAs can be found at www.fda.gov/DrugSafety. Released 12/19/2017

  Six Star Pro Nutrition Life Threaten Products: Do You Have Information about side effects from taking any of Six Star Pro Nutrition products?  This episode will discuss the adverse and life threatening side effects of Six Star Protein Smoothie which consist of 190% iron and can lead to iron toxicity, liver damage and even cause organ failure and death.  Have you or someone you know had any adverse side effects from any Six Star, MuscleTech or Ganeden BC product? Have you filed any complaints with MedWatch, the FDA or any federal or state agency about Six Star Products

On this months episode we talk about spooky Halloween toxicology. What might that be? Listen and find out. Additionally, we cover something even scarier, uncontrollable bleeding. Contributors include Matt Zuckerman, Ed Boyer, Stephanie Weiss, Kavita Babu, and Scott Glazier. As noted in the podcast, here is a link to MedWatch and to the [...]